Business Context and Reporting Period
Company: Spruce Biosciences, Inc. (SPRB)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: Spruce is a late-stage biopharmaceutical company focused on developing therapies for neurological disorders. Its primary product candidates include tralesinidase alfa (TA-ERT) for Sanfilippo Syndrome Type B (MPSIIIB) and tildacerfont for Major Depressive Disorder (MDD) and Congenital Adrenal Hyperplasia (CAH). The company has no approved products and has not generated product revenue.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Collaboration Revenue | $0 | $2,002 |
| Total Operating Expenses | $14,492 | $14,635 |
| Net Loss | $(14,041) | $(11,625) |
| Net Loss Per Share (Basic & Diluted) | $(0.32) | $(0.28) |
| Cash and Cash Equivalents (End of Period) | $25,615 | $81,154 |
| Net Cash Used in Operating Activities | $(12,727) | $(14,958) |
| Accumulated Deficit | $(264,309) | $(208,857) |
| Term Loan Outstanding (Carrying Value) | $1,345 | $1,746 |
Material Changes vs. Prior Period
- Revenue: Collaboration revenue dropped to $0 in Q1 2025 compared to $2.0 million in Q1 2024. The prior period revenue was recognized from the Kaken Pharmaceutical agreement, which was fully recognized by the end of 2024.
- Operating Expenses: Total operating expenses decreased slightly by $0.1 million. Research and Development (R&D) expenses increased by $0.5 million, driven by a $5.7 million acquisition of the SPR202 asset, partially offset by a $3.4 million reduction in clinical activities for the tildacerfont CAH program. General and Administrative (G&A) expenses decreased by $0.7 million, primarily due to lower stock-based compensation.
- Liquidity: Cash and cash equivalents declined by approximately $13.1 million during the quarter, leaving the company with $25.6 million as of March 31, 2025.
- Debt: The company continued to repay its term loan, reducing the carrying value by approximately $0.4 million during the quarter.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. With $25.6 million in cash, the company believes it does not have sufficient working capital to fund operations and debt obligations for the next 12 months without additional financing.
- Nasdaq Delisting: The company was delisted from Nasdaq on April 29, 2025, due to failure to meet the minimum bid price requirement. Trading has moved to the OTC Pink Marketplace. The company is seeking stockholder approval for a reverse stock split to regain compliance.
- Workforce Reduction: In a subsequent event (April 2025), the board approved a 55% workforce reduction to prioritize TA-ERT development. Estimated cash charges are approximately $0.9 million, expected to be recorded in Q2 2025.
- Strategic Shift: The company has shifted focus to TA-ERT, intending to submit a Biologics License Application (BLA) in the first half of 2026. Development of tildacerfont for CAH was discontinued following failed Phase 2b trials.
- Financing Needs: The company requires substantial additional capital to continue clinical development and operations. Failure to secure financing could force delays or elimination of programs.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $25.6 million cash balance against the 12-month burn rate and the impact of the recent 55% workforce reduction on future cash flow.
- Financing Plans: Assess the likelihood and terms of potential equity or debt financing given the recent delisting and "substantial doubt" disclosure.
- Reverse Stock Split: Monitor the outcome of the proposed reverse stock split and the company's ability to regain Nasdaq listing.
- TA-ERT Timeline: Confirm the feasibility of the planned H1 2026 BLA submission for TA-ERT and the status of the required confirmatory Phase 3 trial.
- Debt Covenants: Review the terms of the Silicon Valley Bank term loan (maturing Jan 2026) to ensure compliance with covenants and understand prepayment penalties.